Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo

Clinical Therapeutics

Volumn 23, Issue 9, 2001, Pages 1422-1428

  Harris, Stuart I ^a   Kuss, Michael ^b   Hubbard, Richard C ^b   Goldstein, Jay L ^c  

^a Seaview Research   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

COX 2 inhibitor; Gastrointestinal toxicity; Ketorolac; Naproxen; Nonsteroidal anti inflammatory drugs; Parecoxib sodium

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; KETOROLAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; UNCLASSIFIED DRUG; VALDECOXIB;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DUODENUM ULCER; FEMALE; GASTROINTESTINAL TOXICITY; GASTROSCOPY; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STOMACH ULCER; UPPER GASTROINTESTINAL TRACT;

EID: 0034811819     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80117-X     Document Type: Article

References (23)

1. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs
2. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury
3. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled clinical trial. Celecoxib Long-Term Arthritis Safety Study
4. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial
5. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
6. The classification of cyclooxygenase inhibitors
7. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain
8. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
9. The role of arachidonic acid oxygenation products in pain and inflammation
10. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
11. Cyclooxygenase in biology and disease
12. N-[[(5-Methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration
13. Analgesic activity of single IV doses of parecoxib and ketorolac in postoperative dental pain
14. Toradol® (ketorolac tromethamine)
15. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoathritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
16. Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs
17. Gastrointestinal complications associated with intramuscular ketorolac tromethamine therapy in the elderly
18. Giant duodenal ulcers associated with the postoperative use of ketorolac: Report of three cases
19. Gastric ulcer perforation associated with the use of injectable ketorolac
20. Ketorolac-related giant gastric ulcers
21. Double-blind placebo controlled endoscopic study comparing the mucosal injury seen with an orally and parenterally administered new nonsteroidal analgesic ketorolac tromethamine at therapeutic and supratherapeutic doses
22. A risk-benefit appraisal of injectable NSAIDs in the management of postoperative pain
23. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa